 Novo Nordisk AS NVO , Financial is shelling out 3.3 billion to buy partner Dicerna Pharmaceuticals Inc. DRNA , Financial. Thats 38.25 per share in cash, an 80 premium to the 21.28 closing price of Dicerna on Wednesday, Nov. 17, and the third-highest premium in a deal for a publicly-traded biotech this year, according to BioPharma Dives database. 